• Champalimaud
  • Champalimaud

    The Champalimaud Foundation (CF) is a private, non-profit organisation dedicated to research excellence in biomedical science. Completed in 2010, the Champalimaud Centre for the Unknown (CCU) is a state-of-the-art centre where an unconventional high-risk/high-gain research program (Champalimaud Research –CR), with its three programmes – the Champalimaud Neuroscience Programme (CNP), the Physiology and Cancer Programme (PCP), and the Experimental Clinical Research Programme (ECR), runs in parallel with clinical research in cancer (Champalimaud Clinical Centre – CCC). With an original focus on a systems approach to brain function and behaviour, the CR expanded its organismic research, bringing in molecular and cell biological expertise while ensuring an increased interface between CR and the CCC. CR is organised in 26 research groups (circa 400 researchers) leading independent curiosity-based research programs supported by scientific and technical platforms that combine research and development with high quality services in a plethora of technological areas, and by highly specialised research management and science communication units providing tailored and innovative support. As a result, the CF research community produced a sound scientific record of 723 peer-reviewed original publications (2008-2019; h-index 72; 24,383 summed citations without self-citations) and has been very successful at securing competitive international funding as attested by its 11 active ERC grants.

  • Bruno Costa-Silva, PhD

    Group Leader

    Champalimaud Centre For the Unknown

    Avenida de Brasilia

    1400-038 Lisbon

    Portugal

    bruno.costa-silva@research.fchampalimaud.org

  • Cancer typesPancreatic, Colorectal, Pulmonary, Ovary Cancer
    Clinical applicationDiagnosis and Follow up of Cancer Disease
    Liquid Biopsy sourcePlasma (EDTA Tubes)
    Technologies available for Liquid BiopsyIsolation and characterisation of Extracellular Vesicles
    Key publicationsMaia, J., Batista, S., Couto, N., Gregório, A.C., Bodo, C., Elzanowska, J., Strano Moraes, M.C., Costa-Silva, B#. Population Analysis of Extracellular Vesicles in Microvolumes of Biofluids. BioRxiv. BioRxiv 2020.01.10.895037, doi:10.1101/2020.01.10.895037 (2020). Under review at the Journal of Extracellular Vesicles. Description of a new method that enables the study of EVs populations in microvolumes of non-purified biofluids, which will be key for the study of protein interactions of EVs in this project.

    Rodrigues, G.; Hoshino, A.; Kenific, C. M.; Matei, I. R.; Steiner, L.; Freitas, D.; Kim, H. S.; Oxley, P. R.; Scandariato, I.; Casanova-Salas, I.; Dai, J.; Badwe, C. R.; Gril, B.; Tesic Mark, M.; Dill, B. D.; Molina, H.; Zhang, H.; Benito-Martin, A.; Bojmar, L.; Ararso, Y.; Offer, K.; LaPlant, Q.; Buehring, W.; Wang, H.; Jiang, X.; Lu, T. M.; Liu, Y.; Sabari, J. K.; Shin, S. J.; Narula, N.; Ginter, P. S.; Rajasekhar, V. K.; Healey, J. H.; Meylan, E.; Costa-Silva, B.; et al., Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 2019 Nov 4. Detailed demonstration on how tumor-derived EVs are responsible for the formation of brain niches supportive of brain metastasis. In this work I contributed to the experimental design and discussion of results.design and discussion of results.

    Ferreira, N., Marques, A., Águas, H., Bandarenka, H., Martins, R., Bodo, C., Costa-Silva, B.#*, Fortunato, E*. Label-Free Nanosensing Platform for Breast Cancer Exosome Profiling. ACS Sensors. 2019 Aug 23;4(8):2073-2083. *These authors share the corresponting authorship. Description of a new method, based on Raman spectroscopy that enables the fast distinction between EVs from healthy or cancerous breast epithelium.

    Zheng, J., Hernandez, J. M., Doussot, A., Bojmar, L., Zambirinis, C. P., Costa-Silva, B., et al. Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancreatic cancer. HPB (Oxford) 20, 597-604, doi:10.1016/j.hpb.2017.12.010 (2018). I contributed to the experimental design of a strategy that uses pancreatic fluid as a source of pancreatic cancer biomarkers in EVs.

    Hoshino, A.*, Costa-Silva, B.*, Shen, T. L.*, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015 Nov 19;527(7578):329-35. Here we define for the first time of the biological basis of the patterns of tumor exosomes distribution throughout the organism and how it dictates tumor metastatic organotropism.
  • CSEM
  • CSEM

    CSEM is a groundbreaking innovation hub for precision microtechnologies and digitalization. Our mission is to develop and transfer world-class technologies to the industrial sector. As a bridge and catalyst for the transfer of technology and know-how between science and economy, we continually adapt our research focus to meet industry’s needs. This constant re-adaptation has taken our center, which was founded in 1984, beyond our historic ties with watchmaking. Today, with 500+ employees and 5 sites in Switzerland, we supply a broad range of markets, including medical, life sciences, automotive, machine tools and space exploration, with an even broader range of technological solutions. To enable liquid biopsy applications in the clinic, we support our biological, clinical and industrial partners along the whole value chain with tailor-made solutions, which range from functionalized precision membranes for biological sample preparation to machine learning algorithms for clinical data processing.


    Samantha Paoletti, PhD

    Research & Business Dev. Manager

    Bahnhofstrasse 1

    7302 Landquart

    Switzerland

    Marc Zinggeler, PhD

    R&D Engineer / Project Leader

    Tramstrasse 99

    4132 Muttenz

    Switzerland

    marc.zinggeler@csem.ch

  • Cancer typesNo restrictions
    Clinical applicationNo restrictions
    Liquid Biobsy SourceNo restrictions
    Technologies available for liquid biopsy-Surface coating and functionalization
    -High-precision membranes and substrates
    -Microfluidics and fluidic handling
    -Automatization and robotics
    -Optical and electrochemical sensing
    -Exosome isolation and fractionation
    -Microphysiological systems for disease modeling
    -Machine learning
    Key publicationsF. Kurth, E. Györvary, S. Heub, D. Ledroit, S. Paoletti, K. Renggli, V. Revol, M. Verhulsel, G. Weder, F. Loizeau, Chapter 3 - Organs-on-a-chip engineering, Organ-on-a-chip, academic Press 2020: 47-130

    M. Zinggeler, T. Brandstetter, J. Rühe, Biophysical Insights on the Enrichment of Cancer Cells from Whole Blood by (Affinity) Filtration. Sci Rep 2019; 9: 1246.

    M. Zinggeler, A. Luu-Dinh, C. Schneider, A. Lücke, D. Schlup, T. Offermans, G. Basset, I. Zhurminsky, S. Fricke, Development of Scalable Fabrication Methods for High-precision Membranes, CSEM Scientific and Technical Report 2019: 52

    S. F. Graf, S. Berchtold, T. Volden, V. Revol, Automated, Disposable Sample Preparation Cartridge for Complementary Diagnostics, CSEM Scientific and Technical Report 2019: 54

    S. Heub, G. Voirin, R. Pugin, M. Despont, T. Bauert, A. Tzannis, G. Weder, Disposable Glass Microfluidics for Nucleic Acids Bioassays, CSEM Scientific and Technical Report 2019: 56
  • Hahn-Schickard
  • Hahn-Schickard


    Lab-on-a-chip – from the initial idea to the final product. Hahn-Schickard stands for client- and industry-oriented, application-driven research, development, and production with microsystems. With a total of 250 employees at three sites in the Southwest of Germany, we develop innovative products and technologies in research fields with a strong future impact such as healthcare, internet of things, information and communication technologies, sustainable mobility, as well as environmental and natural resources. At the site in Freiburg, the R+D service provider focusses on automation solutions for diagnostics. Fields of research are the automation of Liquid Biopsy workflows and sample preparation for next generation sequencing. With an in-house pilot line, Hahn-Schickard is able to support the product visions of its customers effectively – from the design stage to serial production.


    Dr. Tobias Hutzenlaub

    Group leader Microfluidic Platforms

    Georges-Koehler-Allee 103

    79110 Freiburg

    Germany

    Tobias.Hutzenlaub@Hahn-Schickard.de


    Peter Jülg

    Group leader Microfluidic Platforms

    Georges-Koehler-Allee 103

    79110 Freiburg

    Germany

    Peter.Juelg@Hahn-Schickard.de

  • Cancer typesColorectal cancer, melanoma, acute lymphoblastic leukemia
    Clinical applicationMonitoring of therapy response, early detection of relapse
    Liquid Biopsy sourceblood, bone marrow
    Technologies available for Liquid BiopsyCentrifugal microfluidic platform consisting of processing device (ready for certification in 2020) and application specific microfluidic chips for ctDNA extraction, qPCR, dPCR and sample preparation for next generation sequencing.
    Key publicationsO. Strohmeier, M. Keller, F. Schwemmer, S. Zehnle, D. Mark, F. von Stetten, R. Zengerle and N. Paust, Centrifugal microfluidic platforms: advanced unit operations and applications, Chem. Soc. Rev., 2015, 44, 6187

    P. Juelg, M. Specht, E. Kipf, M. Lehnert, C. Eckert, M. Keller, T. Hutzenlaub, F. von Stetten, R. Zengerle and N. Paust, Automated serial dilutions for high-dynamic-range assays enabled by fill-level-coupled valving in centrifugal microfluidics, Lab Chip, 2019, 19, 2205

    J.F. Hess, T.A. Kohl, M. Kotrová, K Rönsch, T. Paprotka, V. Mohr, T. Hutzenlaub, M. Brüggemann, R. Zengerle, S. Niemann, N. Paust, Library preparation for next generation sequencing: A review of automation strategies, Biotechnology Advances 2020, in press

    J. Friedrich Hess, M. Kotrová, S. Calabrese, T. Hutzenlaub, R. Zengerle, M. Brueggemann, N. Paust, Automation of amplicon-based library preparation for next generation sequencing by centrifugal microfluidics, 2020, under review
  • Ipatimup
  • Ipatimup
    ipatimup
    ipatimup elbs

    The Institute of Molecular Pathology and Immunology of the University of Porto - Ipatimup – is the leading cancer research institute in Portugal and was established in 1989 under the aegis of the University of Porto. The institute is a founding member of the i3S – Institute for Research and Innovation in Health and of the Porto Comprehensive Cancer Center. The institutes’ objectives are to perform research and graduate training in human pathology, oncobiology and population genetics having as main research fields tumor pathology, population genetics and gene-environment interaction in precancerous and cancerous diseases. The institute is strategically located in a campus with a strong focus of Health, next to the largest hospital in the Region and the Oncology Institute of Porto (IPO) as well as the Faculty of Medicine potentiating the scientific knowledge as a means of delivering innovative clinical and translational research in cancer. The institute has state of the art facilities, including a Proteomic core facility, a Genomic and Bioinformatic core facility, advanced microscopy facility, and an animal house with in vivo experimental models. Finally, Ipatimup has an ISO15189 and CAP accredited diagnostic laboratory devoted to molecular and traditional pathology. This laboratory routinely uses next generation sequencing and digital PCR for tumor and liquid biopsy genetic characterization.

  • Prof. Jose Carlos Machado ELBS

    Prof. José Carlos Machado

    Vice- president

    Rua Júlio Amaral de Carvalho,45
    4200-135 Porto
    Portugal

    josem@ipatimup.pt

    Prof. Luis Costa

    Prof. José Luis Costa

    Principal investigator

    Rua Júlio Amaral de Carvalho,45
    4200-135 Porto
    Portugal

    jcosta@ipatimup.pt

  • Cancer typesLung cancer, breast cancer, colorectal cancer, pancreatic cancer
    Clinical applicationDetection of primary cancer and relapse, therapy monitoring, identification of biomarkers and resistance mechanisms
    Liquid Biobsy SourceBlood, plasma
    Technologies available for liquid biopsyNext generation sequencing, molecular barcode NGS, digital PCR, Nanoparticle Tracking Analysis (NTA)
    Biobanksolid tumors, blood, plasma, urine
    Key publicationsJoana Fernandes Marques, Susana Junqueira-Neto, Jorge Pinheiro, Jose Carlos Machado and Jose Luis Costa (2020) Induction of apoptosis increases sensitivity to detect cancer mutations in plasma. European Journal of Cancer (in press).

    Gil Pinheiro, Tania Pereira, Catarina Dias, Claudia Freitas, Venceslau Hespanhol, Jose Luis Costa, Antonio Cunha, and Helder P. Oliveira (2020) Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS. Scientific Reports (in press).

    Gabriela Fernandes, Maria Jacob, Natalia Martins, Jose Carlos Machado, Venceslau Hespanhol and Jose Luis Costa (2019) Targeted gene next-generation sequencing panel in patients with advanced lung adenocarcinoma: Paving the way for clinical implementation. Cancers 11 (9).

    Joana Fernandes Marques, Joana Pereira Reis, Gabriela Fernandes, Venceslau Hespanhol, Jose Carlos Machado and Jose Luis Costa (2019) Circulating Tumor DNA: A Step into the Future of Cancer Management. Acta Cytologica 63 (6), 456-465.

    Susana Junqueira-Neto, Ines Batista, Jose Luis Costa and Sonia Melo (2019) Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA. Acta Cytologica 63 (6), 479-488.
  • Kyushu University Beppu Hospital
  • Kyushu University Beppu Hospital
    Koshi Mimori
    Kyushu University Beppu Hosptial

    Kyushu University Beppu Hospital was established in 1931 as a branch of the main hospital of Kyushu University in Fukuoka, Japan. We have four medical departments, such as surgery, internal medicine, orthopedics and the radiation in Beppu city. In our department, we have five senior surgeons for operations of 200 digestive system cancers and 100 breast cancers per year and are mentors who orchestrate a dozen graduate students as mentee for research works to disclose the bona-fide truth to eradicate cancers.

    In our department of surgery, we organize a lab for basic and translational research work. At first, we are elucidating the cancer evolution to foster the intratumor heterogeneity (ITH) which have attracted increasing attention in the cancer research field because ITH presumably contributes to the therapeutic and diagnostic difficulties of cancer. We applied the recent technological innovation conducting the multiregional sequencing approach, which has been popularly used to understand ITH (Uchi R, PLoS Genet 2016, Saito T. Nat Commun 2018, Yokoyama A., Nature 2019).

    The second, we have been enthusiastically identifying cancer specific transcriptomes, non-coding genes, genomic alterations and epigenomic aberrations in the body fluid as the "liquid biopsy" system for early diagnosis of postoperative recurrence, concealed cancers at subclinical level in primary tumors and prediction of the susceptibility to any treatments.

    Anyway, it is a great honor for us to join the ELBS meeting, I would appreciate it for the chairperson Prof. Pantel and who may concern.

  • Koshi Mimori

    Prof. Koshi Mimori

    4546 Tsurumihara,

    Beppu 874-0838,

    Japan

    kmimori@beppu.kyushu-u.ac.jp

    Takkaki Masuda

    Takaaki Masuda

    Lecture

    4546 Tsurumihara

    874-0838 Beppu

    Japan

    takaakimas@yahoo.co.jp

  • Cancer typesDigestive system cancers, and breast cancers
    Clinical applicationEarly detection of recurrence and prediction of the susceptibility to treatment
    Liquid Biopsy SourcePlasma, serum from cancer patients
    Technologies available for liquid biopsyTarget re-sequencing, ddPCR
    Key publicationsSugimachi K, Sakimura S, Kuramitsu S, Hirata H, Niida A, Iguchi T, Eguchi H, Masuda T, Morita M, Toh Y, Maehara Y, Suzuki Y, Mimori K. Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy. Br J Cancer. 119(4): 419-23. 2018

    Ueda M, Iguchi T, Masuda T, Nakahara Y, Hirata H, Uchi R, Niida A, Momose K, Sakimura S, Chiba K, Eguchi H, Ito S, Sugimachi K, Yamasaki M, Suzuki Y, Miyano S, Doki Y, Mori M, Mimori K. Oncotarget. 7(38): 62280-91. 2016

    Iwaya T, Fukagawa T, Suzuki Y, Takahashi Y, Sawada G, Ishibashi M, Kurashige J, Sudo T, Tanaka F, Shibata K, Endo F, Katagiri H, Ishida K, Kume K, Nishizuka S, Iinuma H, Wakabayashi G, Mori M, Sasako M, Mimori K. Contrasting expression patterns of histone mRNA and microRNA 760 in patients with gastric cancer. Clin Cancer Res. 19(23):6438-49. 2013

    Mimori K, Fukagawa T, Kosaka Y, Kita Y, Ishikawa K, Etoh T, Iinuma H, Sasako M, Mori M. Hematogenous metastasis in gastric cancer requires isolated tumor cells and expression of vascular endothelial growth factor receptor-1. Clin Cancer Res. 14(9):2609-16. 2008.

    Yokobori T, Iinuma H, Shimamura T, Imoto S, Sugimachi K, Ishii H, Iwatsuki M, Ota D, Ohkuma M, Iwaya T, Nishida N, Kogo R, Sudo T, Tanaka F, Shibata K, Toh H, Sato T, Barnard GF, Fukagawa T, Yamamoto S, Nakanishi H, Sasaki S, Miyano S, Watanabe T, Kuwano H, Mimori K, Pantel K, Mori M. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res. 73(7):2059-69. 2013
  • NIBSC
  • NIBSC
    NIBSC

    The National Institute for Biological Standards and Control (NIBSC, UK) is a centre of the MHRA and a global leader in the characterisation, standardisation and control of biological medicines. NIBSC is the world’s major developer and distributor of World Health Organisation (WHO) International Standards (ISs). WHO ISs are the ‘gold standards’ from which countries and manufacturers can calibrate their own working standards for biological testing. WHO ISs are prepared as a single homogeneous batch of several thousand ampoules, are intended to last many years, are not intended for routine use and act as calibrators of assays and secondary standards to enable the harmonization of the measurement of biological activity through traceability to a single common standard. NIBSC has endorsement from the WHO Expert Committee on Biological Standardization to develop WHO ISs for ctDNA. After the initial focus on the development of WHO ISs for EGFR variants (L858R, exon 19 deletions, and T790M) ctDNA and genomic DNA, NIBSC will expand the portfolio to other biomarkers. ctDNA WHO ISs should ideally be commutable with patients’ samples and allow harmonization of variant percentage, DNA fragment size(s), ctDNA yield, and gene copy numbers. Currently NIBSC is assessing the performance of several matrices with various cell-line derived fragmented DNAs to determine the optimal format for the standards, whilst cross-referencing to patient ctDNA materials and other reference materials already on the market.


    Dr. A. Pia Sanzone

    Group Leader of Non-Invasive Biomarkers and Whole Genome Analysis

    Advanced Therapies Division

    Blanche Lane
    South Mimms
    Potters Bar
    Hertfordshire
    EN6 3QG, U.K.

    Pia.Sanzone@nibsc.org

    Malcolm Hawkins

    Senior Scientist Biotherapeutics Division

    Blanche Lane
    South Mimms
    Potters Bar
    Hertfordshire
    EN6 3QG, U.K.

    Malcolm.Hawkins@nibsc.org

  • Cancer typesInitial focus on EGFR variants (L858R, exon 19 deletions, and T790M) in ctDNA and genomic DNA.
    Clinical applicationctDNA and genomic DNA WHO International Standards that mimic clinical specimens
    Liquid biopsy sourceCell line derived fragmented DNA
    Technologies available for Liquid BiopsyBulk, Freeze-dried fragmented DNA in plasma, digital PCR, NGS
    PublicationsPoster at “Research & Technology Series: Immuno-oncology meeting 10th-11th October 2019, titled: “Development of the First WHO International Standards for ctDNA”
  • Toulouse University Cancer Institute-Oncopole
  • Toulouse University Cancer Institute-Oncopole

    The Oncopole site of Toulouse University Cancer Institute (IUCT-O), together with Cancer Research Center of Toulouse (CRCT), is a Comprehensive Cancer Center member of Organization of European Cancer Institutes (OECI) offering pioneering therapies and technologies. IUCT‑O has three missions, treatment, research (clinical trials, care management and translational research) and teaching, IUCT-located in the heart of a campus grouping together public and private stakeholders involved in the fight against cancer from basic science to clinical trials. The Prospective Biology Unit within the Medical Laboratory of IUCT-O is dedicated to clinical research, innovation and medico-economic evaluation of liquid biopsies in cancers. Together with clinicians and CRCT research teams and the support of CRCT technology cluster (cell imaging, genomic and transcriptomic with single cell analysis …), we take an active part in translational research and clinical trials. Our projects focus on the development of new circulating biological markers for diagnosis, prognosis, longitudinal follow-up of the disease and prediction of therapeutic response, with the molecular analysis of circulating tumor DNA, enrichment and phenotypic characterization of circulating tumor cells, quantification of circulating miRNAs, using innovative technologies such as digital droplet PCR for ctDNA analysis, ISET technology for CTC enrichment or nCounter Analysis System (Nanostring) for miRNA assays.

  • Prof. Gilles

    Prof. Gilles Favre

    Director of the Cancer Research Center of Toulouse

    1 av Irene Joliot-Curie

    31059 Toulouse cedex 9

    France

    favre.gilles@iuct-oncopole.fr

    Pradines

    Anne Pradines, PhD

    Prospective Biology Unit leader

    1 av Irene Joliot-Curie

    31059 Toulouse cedex 9

    France

    pradines.anne@iuct-oncopole.fr

  • Cancer typesSolid tumors (lung, melanoma, breast, ovarian cancer, prostate)
    Clinical applicationEarly detection of primary cancer and relapse, monitoring of therapy response, identification of therapy targets and resistance mechanisms
    Liquid Biobsy SourceBlood, plasma
    Technologies available for liquid biopsyddPCR, Target re-sequencing
    BiobankPlasma, PBMC
    Key publicationsGuibert N, Pradines A, Favre G, Mazieres J. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Eur Respir Rev. 2020;29(155):190052.

    Guibert N, Jones G, Beeler JF, et al. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2019;137:1–6

    Keller L, Guibet N, Delaunay M, Casanova A, Farella M, Brayer S, Gilhodes J, Martin E, Favre G, Pradines A, Meyer N. Early ctDNA variation predicts tumor response in melanoma patients treated with immunotherapy. Acta Dermato 2019 ; 99: 206–210.

    Guibert N, Delaunay M, Lusque A, et al. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer. 2018;120:108–112.

    Guibert N, Pradines A, Farella M, Casanova A, Gouin S, Keller L, Favre G, Mazieres J. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma. Lung Cancer 2016; 100: 1-4.
  • University Medical Center Hamburg-Eppendorf
  • University Medical Center Hamburg-Eppendorf
    Network at UKE
    The Liquid Biopsy Translational Research Network at UKE
    It is part of the Univerity Cancer Center Hamburg (UCCH), one of the top cancer center ("Onkologisches Spitzenzentren")
    Funding
    Funding
    Individual projects are funded by highly competitive EU grants (ERC, IMI, ERA-Net Transcan, Marie Curie-Sklodowaska Training network).

    The Liquid Biopsy Translational Research Network at UKE has been established by Klaus Pantel and is part of the University Cancer Center Hamburg (UCCH, Director: Prof. Carsten Bokemeyer), one of the top cancer centers („Onkologische Spitzenzentren“) funded by the German Cancer Aid („Deutsche Krebshilfe“) which also funds a novel post-graduate training center for clinical and translational scientists („Mildred-Scheel Nachwuchszentrum“) at UCCH focusing on cancer cell dissemination/metastasis and liquid biopsy. The network has published more than 300 reports (mostly on clinical studies in patients with various types of solid tumors) and individual projects are funded by highly competitive EU grants (ERC, IMI, ERA-Net TRANSCAN, Marie Curie-Sklodowska Training networks).

  • Prof Klaus Pantel

    Prof. Klaus Pantel

    Chairman of Institut of Tumorbiologie

    Martinistr. 52

    20246 Hamburg

    Germany

    pantel@uke.de

    Natalie Reimers

    Natalie Reimers, PhD

    Project manager

    Martinistr. 52

    20246 Hamburg

    Germany

    nreimers@uke.de

  • Cancer typesSolid tumors (e.g., prostate, breast, lung, GI-tract, melanoma, bladder, cervical cancer)
    Clinical applicationEarly detection of primary cancer and relaps (MRD), monitoring of therapy response, identification of therapy targets and resistance mechanisms
    Liquid Biopsy sourceBlood, plasma, bone marrow
    Technologies available for Liquid BiopsyCellSearch; Parsortix; others
    BiobankSolid tumors (CTCs, plasma)
    Key publicationsKeller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer 2019;19: 553-67.

    Pantel K, Alix-Panabieres C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16: 409-24.

    Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ,...Pierga JY, Pantel K. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. JNCI. 2018.

    Werner S, Brors B, Eick J, Marques E, Pogenberg V, Parret A, Kemming D, Wood AW, Edgren H, Neubauer H, Streichert T, Riethdorf S, Bedi U, Baccelli I, Jucker M, Eils R, Fehm T, Trumpp A, Johnsen SA, Klefstrom J, Wilmanns M, Muller V, Pantel K*, Wikman H*. Suppression of early hematogenous dissemination of human breast cancer cells to bone marrow by retinoic Acid-induced 2. Cancer Discov. 2015;5: 506-19. (*shared senior authorship)

    Muller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, Matschke J, Langer-Freitag S, Gasch C, Stoupiec M, Mauermann O, Peine S, Glatzel M, Speicher MR, Geigl JB, Westphal M, Pantel K*, Riethdorf S. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014;6: 247ra101. (*shared senior authorship)
  • University of Patras
  • University of Patras
    uni patras
    University of Patras
    uni patras 2

    University of Patras was founded in 1964. It has 3.931 Postgraduate students, 35 Departments, 161 Laboratories and 17 Clinics, The Department of Biology was founded in 1967 and is the first Department of Biology founded in Greece. The Department provides studies on all aspects of Biological science. The research activities of the members of the department cover a wide range of cutting-edge biological technologies. The Department of Biology is housed in a building of 25000 sq.m. and has a significant infrastructure of scientific equipment distributed in educational and research laboratories.

    The Laboratory of Biochemistry/Liquid Biopsy situated in the Department of Biology is focused on the Evaluation of signal transduction pathways in Cancer Cells. Enumeration and Characterization of Circulating and Disseminated Tumor Cells (CTCs/DTCs). Investigation of the crosstalk between CTCs and Immune Cells. Development of innovative diagnostic tools for the detection of circulating tumor cells (CTCs) in patients' blood. Assessment of tailor-made substrates for three-dimensional (3D) cultures of tumor cells and CTCs to test drug efficacy (laser-made 3D scaffolds induced on natural biopolymer films). Participation in the development of hyperspectral artificial vision-guided robotic microscope for fixed cells and live cell imaging (CTCs).

    Galatea Kallergi, Msc, PhD

    Assistant Professor of Biochemistry, Division of Genetics, Cell and Developmental Biology

    Department of Biology
    University of Patras
    26504 Patras
    Greece

    galkallergi@gmail.com

  • Cancer typesBreast Cancer, Colon Cancer, NSCLC, SCLC etc
    Clinical applicationIdentification of new biomarkers and therapeutic targets on CTCs, Exosomes etc. Development of new methods for culturing and imaging CTCs for testing drug efficacy.
    Liquid Biopsy sourceBlood, plasma, Bone marrow
    Technologies available for Liquid BiopsyHigh Resolution Image Analysis systems (ZEISS Axioscope), Transmission Electron Microscope (TEM), Scanning Electron Microscope (SEM), Real Time -PCR etc
    BiobankIsolated CTCs from patients with solid tumors, ISET Filters with CTCs from NSCLC and Breast Cancer patients.
    Key publicationsG. Kallergi, O. Hoffmann, AK. Bittner, L. Papadimitriou, N Zacharopoulou, M. Zervakis, S. Sfakianakis, C. Stournaras, V. Georgoulias, R. Kimmig, S. Kasimir-Bauer. CXCR4 and JUNB double positive disseminated tumor cells are frequently detected in breast cancer patients at primary diagnosis (Under press in Therapeutic Advances in Medical Oncology).

    G. Kallergi, V. Tsintari, S Sfakianakis, E.S. Bei, N. Zacharopoulou, C. Stournaras, M. Zervakis and V. Georgoulias The prognostic value of JUNB-positive CTCs in metastatic breast cancer; from bioinformatics to immunophenotype. Breast Cancer Res. 2019 Aug 1;21(1):86..

    G. Kallergi, D. Aggouraki, N. Zacharopoulou, C. Stournaras, V. Georgoulias, S.S. Martin. Evaluation of microtentacles on Circulating Tumor Cells (CTCs); Interaction between CTCs and blood cells through cytoskeletal proteins. Breast Cancer Res. 2018 Jul 5;20(1):67.

    G, Kallergi, E.K. Vetsika, D. Agouraki, E. Lagoudaki, A. Koutsopoulos, F. Koinis , P. Katsarlinos, M. Trypaki, I. Messaritakis, C. Stournaras, V. Georgoulias, A. Kotsakis. Evaluation of PD-L1/PD-1 on Circulating Tumor Cells (CTCs) in patients with advanced non-small cell lung cancer (NSCLC). Therapeutic Advances in Medical Oncology Journal, 2018 Jan 15;10.

    Agelaki, Melina Dragolia, H. Markonanolaki, S. Alkahtani, Ch. Stournaras, V. Georgoulias, G. Kallergi, Phenotypic characterization of circulating tumor cells (CTCs) in triple negative breast cancer patients (TNBC), Oncotarget 2017 Jan 17;8(3):5309-5322.